glp-1 obesity drug news Game changing' data: New drugs tied to major weight loss, may reduce CV risk The GLP-1 Access Gap: Mapping

Description

The study utilized a single-blind, randomized, placebo-controlled, crossover design, combined with functional magnetic resonance imaging (fMRI), to analyze the performance of 54 participants (30 with normal insulin sensitivity and 24 with impaired insulin sensitivity) on sensory associative learning tasks while receiving liraglutide and placebo treatments

Table 1: Key Findings on Natural GLP-1 in Joint Fluid and Arthritis Research shows GLP-1 is present in synovial fluid , supporting the idea that therapies targeting this hormone could directly influence joint inflammation

40 In the LIVE trial, which evaluated the effects of liraglutide on LV function in stable chronic HF patients with and without diabetes, at the end of treatment patients from the liraglutide group were able to walk 28 65 m longer during the 6MWT, compared with 3 89 m for patients in the placebo group, with a mean difference of 24 m

Finally, the combination of a GLP-1 receptor agonist and amylin agonism by cagrilintide/semaglutide is currently under investigation (Table 1)

As shown in this study, despite receiving PTA and PTE under the Hatch Waxman Act to compensate for the loss of any patent term of the main compound once a drug is approved, in this hyper financialized economy it is not enough